Mesoblast Sees 60% Increase in Ryoncil® Sales for December Quarter
Source: Kapitales Research
Key Highlights:
Mesoblast’s Ryoncil® (remestemcel-L-rknd) achieved sales of US$35.1 million for the quarter ending December 31, 2025, marking a 60% growth compared to the previous quarter.
This growth is driven by Ryoncil® being the sole FDA-approved treatment for pediatric patients with steroid-refractory acute graft-versus-host disease (SR-aGvHD).
The company has secured a new US$125 million five-year facility to support future growth and strategic flexibility.
Sales Growth and Financial Update
Mesoblast Limited (ASX: MSB, Nasdaq: MESO), a global leader in allogeneic cell-based therapies, reported that Ryoncil® achieved US$35.1 million in sales for the quarter ending December 31, 2025. This marks a 60% increase over the US$21.9 million in sales reported in the previous quarter (ended September 30, 2025).
Ryoncil® is the first FDA-approved mesenchymal stromal cell (MSC) therapy specifically intended for treating steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients. The sales growth is driven by expanding market acceptance and strong demand from the pediatric segment. Mesoblast is also preparing for a pivotal trial of Ryoncil® as a second-line treatment for adult SR-aGvHD, a significantly larger market opportunity than the pediatric segment.
Strategic Financing and Balance Sheet Strengthening
In conjunction with the sales growth, Mesoblast secured a US$125 million financing facility from its largest shareholder, which significantly reduces the company’s cost of capital. The new five-year interest-only facility has a much lower overall cost compared to previous facilities. This new financial agreement enables Mesoblast to repay its existing senior secured loan and partially reduce its subordinated royalty facility, which is expected to be fully repaid by mid-2026.
The lower-cost financing offers Mesoblast greater flexibility for strategic partnerships and future commercialization efforts, including expanding Ryoncil®'s label indications.
Looking Ahead: Expansion and Growth Opportunities
Mesoblast remains committed to expanding Ryoncil® into new indications and is pursuing additional collaborations to drive label expansion. In addition to SR-aGvHD in adults, Ryoncil® is being developed for other inflammatory diseases, and Mesoblast continues to explore strategic collaborations in international markets.
The new financial flexibility provided by the facility will enable Mesoblast to further develop Ryoncil® and its pipeline of cell-based therapies, which also includes rexlemestrocel-L for heart failure and chronic low back pain.
Outlook
The continued growth in Ryoncil® sales, along with the recent financing, positions Mesoblast to advance its clinical development programs and expand its market presence. The company is optimistic about its ability to leverage its strong balance sheet to further commercialize its therapies, particularly in the expanding field of cell-based regenerative medicine.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Mesoblast Sees 60% Increase in Ryoncil® Sales for December Quarter
Key Highlights:
Sales Growth and Financial Update
Mesoblast Limited (ASX: MSB, Nasdaq: MESO), a global leader in allogeneic cell-based therapies, reported that Ryoncil® achieved US$35.1 million in sales for the quarter ending December 31, 2025. This marks a 60% increase over the US$21.9 million in sales reported in the previous quarter (ended September 30, 2025).
Ryoncil® is the first FDA-approved mesenchymal stromal cell (MSC) therapy specifically intended for treating steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients. The sales growth is driven by expanding market acceptance and strong demand from the pediatric segment. Mesoblast is also preparing for a pivotal trial of Ryoncil® as a second-line treatment for adult SR-aGvHD, a significantly larger market opportunity than the pediatric segment.
Strategic Financing and Balance Sheet Strengthening
In conjunction with the sales growth, Mesoblast secured a US$125 million financing facility from its largest shareholder, which significantly reduces the company’s cost of capital. The new five-year interest-only facility has a much lower overall cost compared to previous facilities. This new financial agreement enables Mesoblast to repay its existing senior secured loan and partially reduce its subordinated royalty facility, which is expected to be fully repaid by mid-2026.
The lower-cost financing offers Mesoblast greater flexibility for strategic partnerships and future commercialization efforts, including expanding Ryoncil®'s label indications.
Looking Ahead: Expansion and Growth Opportunities
Mesoblast remains committed to expanding Ryoncil® into new indications and is pursuing additional collaborations to drive label expansion. In addition to SR-aGvHD in adults, Ryoncil® is being developed for other inflammatory diseases, and Mesoblast continues to explore strategic collaborations in international markets.
The new financial flexibility provided by the facility will enable Mesoblast to further develop Ryoncil® and its pipeline of cell-based therapies, which also includes rexlemestrocel-L for heart failure and chronic low back pain.
Outlook
The continued growth in Ryoncil® sales, along with the recent financing, positions Mesoblast to advance its clinical development programs and expand its market presence. The company is optimistic about its ability to leverage its strong balance sheet to further commercialize its therapies, particularly in the expanding field of cell-based regenerative medicine.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au